Convection-enhanced delivery: From mechanisms to clinical drug delivery for diseases of the central nervous system

Neurologia Medico-Chirurgica

Volumn 52, Issue 8, 2012, Pages 531-538

  Saito, Ryuta ^a   Tominaga, Teiji ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Blood brain barrier; Brain tumor; Central nervous system; Convection enhanced delivery; Drug delivery

Indexed keywords

4 AMINOBUTYRIC ACID; ADENOSINE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN SINGLE CHAIN FRAGMENT VARIABLE; ANTICONVULSIVE AGENT; ANTINEOPLASTIC AGENT; AROMATIC LEVO AMINO ACID DECARBOXYLASE; BOTULINUM TOXIN; CALCIUM CHANNEL BLOCKING AGENT; CARMUSTINE; CINTREDEKIN BESUDOTOX; COTARA; GLUCOSYLCERAMIDASE; GLUTAMATE DECARBOXYLASE; HYBRID PROTEIN; IMMUNOMODULATING AGENT; INTERLEUKIN 13 PSEUDOMONAS EXOTOXIN; LIPOSOME; MEMBRANE METALLOENDOPEPTIDASE; MUSCIMOL; NBI 3001; NEURTURIN; NIMUSTINE; PACLITAXEL; PARVOVIRUS VECTOR; TOPOTECAN; TRABEDERSEN; TRANSFERRIN DIPHTHERIA TOXIN CONJUGATE; TRANSFORMING GROWTH FACTOR ALPHA PSEUDOMONAS EXOTOXIN CONJUGATE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALZHEIMER DISEASE; BLOOD BRAIN BARRIER; BRAIN TUMOR; CANCER CHEMOTHERAPY; CENTRAL NERVOUS SYSTEM DISEASE; CONTROLLED RELEASE FORMULATION; CONVECTION ENHANCED DELIVERY; DISTRIBUTION VOLUME; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG SAFETY; EPILEPSY; GAUCHER DISEASE; GLIOBLASTOMA; HUMAN; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; REVIEW;

ANTINEOPLASTIC AGENTS; BLOOD-BRAIN BARRIER; CENTRAL NERVOUS SYSTEM DISEASES; CENTRAL NERVOUS SYSTEM NEOPLASMS; CONVECTION; DRUG DELIVERY SYSTEMS; FORECASTING; GLIOBLASTOMA; GLIOMA; HUMANS; INFUSIONS, INTRALESIONAL;

EID: 84865487983     PISSN: 04708105     EISSN: 13498029     Source Type: Journal    
DOI: 10.2176/nmc.52.531     Document Type: Review

References (58)

1. Bobo RH, Laske DW, Akbasak A, Morrison PF, Dedrick RL, Oldfield EH: Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci U S A 91: 2076-2080, 1994
2. Bogdahn U, Hau P, Stockhammer G, Venkataramana NK, Mahapatra AK, Suri A, Balasubramaniam A, Nair S, Oliushine V, Parfenov V, Poverennova I, Zaaroor M, Jachimczak P, Ludwig S, Schmaus S, Heinrichs H, Schlingensiepen KH: Targeted therapy for high-grade glioma with the TGF-beta2 inhibitor trabedersen: results of a randomized and controlled phase IIb study. Neuro Oncol 13: 132-142, 2011
3. Boucher Y, Baxter LT, Jain RK: Interstitial pressure gradients in tissue-isolated and subcutaneous tumors: implications for therapy. Cancer Res 50: 4478-4484, 1990
4. Boucher Y, Jain RK: Microvascular pressure is the principal driving force for interstitial hypertension in solid tumors: implications for vascular collapse. Cancer Res 52: 5110-5114, 1992
5. Brem H, Piantadosi S, Burger PC, Walker M, Selker R, Vick NA, Black K, Sisti M, Brem S, Mohr G, Muller P, Morawetz R, Schold SC: Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymerbrain Tumor Treatment Group. Lancet 345: 1008-1012, 1995
6. Bruce JN, Fine RL, Canoll P, Yun J, Kennedy BC, Rosenfeld SS, Sands SA, Surapaneni K, Lai R, Yanes CL, Bagiella E, DeLaPaz RL: Regression of recurrent malignant gliomas with convection-enhanced delivery of topotecan. Neurosurgery 69: 1272-1280, 2011
7. Buonerba C, Di Lorenzo G, Marinelli A, Federico P, Palmieri G, Imbimbo M, Conti P, Peluso G, De Placido S, Sampson JH: A comprehensive outlook on intracerebral therapy of malignant gliomas. Crit Rev Oncol Hematol 80: 54-68, 2011
8. Chen MY, Hoffer A, Morrison PF, Hamilton JF, Hughes J, Schlageter KS, Lee J, Kelly BR, Oldfield EH: Surface properties, more than size, limiting convective distribution of virus-sized particles and viruses in the central nervous system. J Neurosurg 103: 311-319, 2005
9. Debinski W, Tatter SB: Convection-enhanced delivery for the treatment of brain tumors. Expert Rev Neurother 9: 1519-1527, 2009
10. Eberling JL, JagustWJ, Christine CW, Starr P, Larson P, Bankiewicz KS, Aminoff MJ: Results from a phase I safety trial of hAADC gene therapy for Parkinson disease. Neurology 70: 1980-1983, 2008
11. Engelhard HH: The role of interstitial BCNU chemotherapy in the treatment of malignant glioma. Surg Neurol 53: 458-464, 2000
12. Fiandaca MS, Bankiewicz KS: Gene therapy for Parkinson's disease: from non-human primates to humans. Curr Opin Mol Ther 12: 519-529, 2010
13. Groothuis DR: The blood-brain and blood-tumor barriers: a review of strategies for increasing drug delivery. Neuro Oncol 2: 45-59, 2000
14. Heiss JD, Walbridge S, Asthagiri AR, Lonser RR: Image-guided convection-enhanced delivery of muscimol to the primate brain. J Neurosurg 112: 790-795, 2010
15. Husain SR, Puri RK: Interleukin-13 receptor-directed cytotoxin for malignant glioma therapy: from bench to bedside. J Neurooncol 65: 37-48, 2003
16. Jarboe JS, Johnson KR, Choi Y, Lonser RR, Park JK: Expression of interleukin-13 receptor alpha2 in glioblastoma multiforme: implications for targeted therapies. Cancer Res 67: 7983-7986, 2007
17. Juillerat-Jeanneret L: The targeted delivery of cancer drugs across the blood-brain barrier: chemical modifications of drugs or drug-nanoparticles? Drug Discov Today 13: 1099-1106, 2008
18. Kaplitt MG, Feigin A, Tang C, Fitzsimons HL, Mattis P, Lawlor PA, Bland RJ, Young D, Strybing K, Eidelberg D, During MJ: Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial. Lancet 369: 2097-2105, 2007
19. Kawakami M, Kawakami K, Puri RK: Interleukin-4-Pseudomonas exotoxin chimeric fusion protein for malignant glioma therapy. J Neurooncol 65: 15-25, 2003
20. Kells AP, Hadaczek P, Yin D, Bringas J, Varenika V, Forsayeth J, Bankiewicz KS: Efficient gene therapybased method for the delivery of therapeutics to primate cortex. Proc Natl Acad Sci U S A 106: 2407-2411, 2009
21. Krauze MT, Saito R, Noble C, Bringas J, Forsayeth J, McKnight TR, Park J, Bankiewicz KS: Effects of the perivascular space on convection-enhanced delivery of liposomes in primate putamen. Exp Neurol 196: 104-111, 2005
22. Krauze MT, Saito R, Noble C, Tamas M, Bringas J, Park JW, Berger MS, Bankiewicz K: Reflux-free cannula for convection-enhanced high-speed delivery of therapeutic agents. J Neurosurg 103: 923-929, 2005
23. Kunwar S, Chang S, Westphal M, Vogelbaum M, Sampson J, Barnett G, Shaffrey M, Ram Z, Piepmeier J, Prados M, Croteau D, Pedain C, Leland P, Husain SR, Joshi BH, Puri RK: Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma. Neuro Oncol 12: 871-881, 2010
24. Kunwar S, Prados MD, Chang SM, Berger MS, Lang FF, Piepmeier JM, Sampson JH, Ram Z, Gutin PH, Gibbons RD, Aldape KD, Croteau DJ, Sherman JW, Puri RK: Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group. J Clin Oncol 25: 837-844, 2007
25. Laske DW, Youle RJ, Oldfield EH: Tumor regression with regional distribution of the targeted toxin TFCRM107 in patients with malignant brain tumors. Nat Med 3: 1362-1368, 1997
26. LeWitt PA, Rezai AR, Leehey MA, Ojemann SG, Flaherty AW, Eskandar EN, Kostyk SK, Thomas K, Sarkar A, Siddiqui MS, Tatter SB, Schwalb JM, Poston KL, Henderson JM, Kurlan RM, Richard IH, Van Meter L, Sapan CV, DuringMJ, KaplittMG, Feigin A: AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial. Lancet Neurol 10: 309-319, 2011
27. Lidar Z, Mardor Y, Jonas T, Pfeffer R, FaibelM, Nass D, Hadani M, Ram Z: Convection-enhanced delivery of paclitaxel for the treatment of recurrent malignant glioma: a phase I/II clinical study. J Neurosurg 100: 472-479, 2004
28. Linninger AA XM: Drug delivery into the human brain. Drug Delivery 1985: 163-168, 2001
29. Lonser RR, Walbridge S, Garmestani K, Butman JA, Walters HA, Vortmeyer AO, Morrison PF, Brechbiel MW, Oldfield EH: Successful and safe perfusion of the primate brainstem: in vivo magnetic resonance imaging of macromolecular distribution during infusion. J Neurosurg 97: 905-913, 2002
30. Lonser RR, Warren KE, Butman JA, Quezado Z, Robison RA, Walbridge S, Schiffman R, Merrill M, WalkerML, Park DM, Croteau D, Brady RO, Oldfield EH: Real-time image-guided direct convective perfusion of intrinsic brainstem lesions. Technical note. J Neurosurg 107: 190-197, 2007
31. MacKay JA, Deen DF, Szoka FC Jr: Distribution in brain of liposomes after convection enhanced delivery; modulation by particle charge, particle diameter, and presence of steric coating. Brain Res 1035: 139-153, 2005
32. Mardor Y, Rahav O, Zauberman Y, Lidar Z, Ocherashvilli A, Daniels D, Roth Y, Maier SE, Orenstein A, Ram Z: Convection-enhanced drug delivery: increased efficacy and magnetic resonance image monitoring. Cancer Res 65: 6858-6863, 2005
33. Miners JS, Barua N, Kehoe PG, Gill S, Love S: Abdegrading enzymes: potential for treatment of Alzheimer disease. J Neuropathol Exp Neurol 70: 944-959, 2011
34. Murad GJ, Walbridge S, Morrison PF, Szerlip N, Butman JA, Oldfield EH, Lonser RR: Image-guided convection-enhanced delivery of gemcitabine to the brainstem. J Neurosurg 106: 351-356, 2007
35. Navalitloha Y, Schwartz ES, Groothuis EN, Allen CV, Levy RM, Groothuis DR: Therapeutic implications of tumor interstitial fluid pressure in subcutaneous RG-2 tumors. Neuro Oncol 8: 227-233, 2006
36. Netti PA, Baxter LT, Boucher Y, Skalak R, Jain RK: Time-dependent behavior of interstitial fluid pressure in solid tumors: implications for drug delivery. Cancer Res 55: 5451-5458, 1995
37. Pardridge WM: The blood-brain barrier: bottleneck in brain drug development. NeuroRx 2: 3-14, 2005
38. Patel SJ, Shapiro WR, Laske DW, Jensen RL, Asher AL, Wessels BW, Carpenter SP, Shan JS: Safety and feasibility of convection-enhanced delivery of Cotara for the treatment of malignant glioma: initial experience in 51 patients. Neurosurgery 56: 1243-1253, 2005
39. Raghavan R, Brady ML, Rodriguez-Ponce MI, Hartlep A, Pedain C, Sampson JH: Convection-enhanced delivery of therapeutics for brain disease, and its optimization. Neurosurg Focus 20(4): E12, 2006
40. Richardson RM, Gimenez F, Salegio EA, Su X, Bringas J, Berger MS, Bankiewicz KS: T2 imaging in monitoring of intraparenchymal real-time convection-enhanced delivery. Neurosurgery 69: 154-163, 2011
41. Rogawski MA: Convection-enhanced delivery in the treatment of epilepsy. Neurotherapeutics 6: 344-351, 2009
42. Ryan DA, Mastrangelo MA, Narrow WC, Sullivan MA, Federoff HJ, Bowers WJ: Abeta-directed singlechain antibody delivery via a serotype-1 AAV vector improves learning behavior and pathology in Alzheimer's disease mice. Mol Ther 18: 1471-1481, 2010
43. Saito R, Bringas JR, McKnight TR, Wendland MF, Mamot C, Drummond DC, Kirpotin DB, Park JW, Berger MS, Bankiewicz KS: Distribution of liposomes into brain and rat brain tumor models by convection-enhanced delivery monitored with magnetic resonance imaging. Cancer Res 64: 2572-2579, 2004
44. Saito R, Krauze MT, Bringas JR, Noble C, McKnight TR, Jackson P, Wendland MF, Mamot C, Drummond DC, Kirpotin DB, Hong K, Berger MS, Park JW, Bankiewicz KS: Gadolinium-loaded liposomes allow for real-time magnetic resonance imaging of convection-enhanced delivery in the primate brain. Exp Neurol 196: 381-389, 2005
45. Saito R, Krauze MT, Noble CO, Tamas M, Drummond DC, Kirpotin DB, Berger MS, Park JW, Bankiewicz KS: Tissue affinity of the infusate affects the distribution volume during convection-enhanced delivery into rodent brains: implications for local drug delivery. J Neurosci Methods 154: 225-232, 2006
46. Saito R, Sonoda Y, Kumabe T, Nagamatsu K, Watanabe M, Tominaga T: Regression of recurrent glioblastoma infiltrating the brainstem after convection-enhanced delivery of nimustine hydrochloride. J Neurosurg Pediatr 7: 522-526, 2011
47. Sampson JH, Akabani G, Archer GE, Berger MS, Coleman RE, Friedman AH, Friedman HS, Greer K, Herndon JE 2nd, Kunwar S, McLendon RE, Paolino A, Petry NA, Provenzale JM, Reardon DA, Wong TZ, ZalutskyMR, Pastan I, Bigner DD: Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors. Neuro Oncol 10: 320-329, 2008
48. Sampson JH, Archer G, Pedain C, Wembacher-Schroder E, Westphal M, Kunwar S, Vogelbaum MA, Coan A, Herndon JE, Raghavan R, Brady ML, Reardon DA, Friedman AH, Friedman HS, Rodriguez-Ponce MI, Chang SM, Mittermeyer S, Croteau D, Puri RK: Poor drug distribution as a possible explanation for the results of the PRECISE trial. J Neurosurg 113: 301-309, 2010
49. Sampson JH, BradyML, Petry NA, Croteau D, Friedman AH, Friedman HS, Wong T, Bigner DD, Pastan I, Puri RK, Pedain C: Intracerebral infusate distribution by convection-enhanced delivery in humans with malignant gliomas: descriptive effects of target anatomy and catheter positioning. Neurosurgery 60(2 Suppl 1): ONS89-ONS99, 2007
50. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996, 2005
51. Tanner PG, Holtmannspotter M, Tonn JC, Goldbrunner R: Effects of drug efflux on convection-enhanced paclitaxel delivery to malignant gliomas: technical note. Neurosurgery 61: E880-E882, 2007
52. Varenika V, Dickinson P, Bringas J, LeCouteur R, Higgins R, Park J, FiandacaM, Berger M, Sampson J, Bankiewicz K: Detection of infusate leakage in the brain using real-time imaging of convection-enhanced delivery. J Neurosurg 109: 874-880, 2008
53. Vavra M, Ali MJ, Kang EW, Navalitloha Y, Ebert A, Allen CV, Groothuis DR: Comparative pharmacokinetics of 14C-sucrose in RG-2 rat gliomas after intravenous and convection-enhanced delivery. Neuro Oncol 6: 104-112, 2004
54. Vogelbaum MA: Convection enhanced delivery for the treatment of malignant gliomas: symposium review. J Neurooncol 73: 57-69, 2005
55. Vogelbaum MA, Sampson JH, Kunwar S, Chang SM, ShaffreyM, Asher AL, Lang FF, Croteau D, Parker K, Grahn AY, Sherman JW, Husain SR, Puri RK: Convection-enhanced delivery of cintredekin besudotox (interleukin-13-PE38QQR) followed by radiation therapy with and without temozolomide in newly diagnosed malignant gliomas: phase 1 study of final safety results. Neurosurgery 61: 1031-1038, 2007
56. Weaver M, Laske DW: Transferrin receptor ligandtargeted toxin conjugate (Tf-CRM107) for therapy of malignant gliomas. J Neurooncol 65: 3-13, 2003
57. Weber F, Asher A, Bucholz R, Berger M, Prados M, Chang S, Bruce J, Hall W, Rainov NG, Westphal M, Warnick RE, Rand RW, Floeth F, Rommel F, Pan H, Hingorani VN, Puri RK: Safety, tolerability, and tumor response of IL4-Pseudomonas exotoxin (NBI-3001) in patients with recurrent malignant glioma. J Neurooncol 64: 125-137, 2003
58. Westphal M, Hilt DC, Bortey E, Delavault P, Olivares R, Warnke PC, Whittle IR, Jaaskelainen J, Ram Z: A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol 5: 79-88, 2003